Health care stocks were declining premarket Friday as the Health Care Select Sector SPDR Fund (XLV) was down 0.4% and the iShares Biotechnology ETF (IBB) was 0.2% lower recently.
Novo Nordisk (NVO) shares rose past 11% after the company said its phase 1b/2a clinical trial of amycretin in people with overweight or obesity showed positive results.
Allurion Technologies (ALUR) shares surged by more than 364% after the company said it plans to initiate a clinical study to investigate the combination of the Allurion program with GLP-1 agonists to improve muscle mass and overall body composition.
Moderna (MRNA) shares were up over 1% after the company said it has been awarded a tender to supply its Covid-19 vaccine in the European Union, Norway and North Macedonia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。